Zobrazeno 1 - 10
of 29
pro vyhledávání: '"David N Soleimani-Meigooni"'
Autor:
Nidhi S. Mundada, Julio C. Rojas, Lawren Vandevrede, Elisabeth H. Thijssen, Leonardo Iaccarino, Obiora C. Okoye, Ranjani Shankar, David N. Soleimani-Meigooni, Argentina L. Lago, Bruce L. Miller, Charlotte E. Teunissen, Hillary Heuer, Howie J. Rosen, Jeffrey L. Dage, William J. Jagust, Gil D. Rabinovici, Adam L. Boxer, Renaud La Joie
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-13 (2023)
Abstract Background Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer’s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences between amyloid-posit
Externí odkaz:
https://doaj.org/article/3dbc3ee43d5140a18da1d39288aff8ab
Publikováno v:
Journal of Nuclear Medicine. 64:822-824
Autor:
Jeremy A Tanner, Leonardo Iaccarino, Lauren Edwards, Breton M Asken, Maria L Gorno-Tempini, Joel H Kramer, Julie Pham, David C Perry, Katherine Possin, Maura Malpetti, Taylor Mellinger, Bruce L Miller, Zachary Miller, Nidhi S Mundada, Howard J Rosen, David N Soleimani-Meigooni, Amelia Strom, Renaud La Joie, Gil D Rabinovici
Publikováno v:
Brain
Early-onset (age < 65) Alzheimer’s disease is associated with greater non-amnestic cognitive symptoms and neuropathological burden than late-onset disease. It is not fully understood whether these groups also differ in the associations between mole
Autor:
David N. Soleimani‐Meigooni, Wesley P. Thomas, Matthias Brendel, Stephanie Vento, Hilary W. Heuer, Peter A. Ljubenkov, Julio C. Rojas, Miranda Chen, Leonardo Iaccarino, Renaud La Joie, Nidhi S. Mundada, Bradley F. Boeve, Murray Grossman, Bradford C. Dickerson, David J. Irwin, Irene Litvan, Alex Pantelyat, Carmela Tartaglia, Gil D. Rabinovici, Suzanne L. Baker, Adam L. Boxer
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Nidhi S. Mundada, Elisabeth H Thijssen, Leonardo Iaccarino, Obiora C Okoye, Ranjani Shankar, David N. Soleimani‐Meigooni, Lawren VandeVrede, Argentina Lario Lago, Bruce L. Miller, Charlotte E. Teunissen, Julio C. Rojas, Jeffrey L Dage, Gil D. Rabinovici, Adam L. Boxer, Renaud La Joie
Publikováno v:
Mundada, N S, Thijssen, E H, Iaccarino, L, Okoye, O C, Shankar, R, Soleimani-Meigooni, D N, VandeVrede, L, Lago, A L, Miller, B L, Teunissen, C E, Rojas, J C, Dage, J L, Rabinovici, G D, Boxer, A L & la Joie, R 2022, ' Head-to-head comparison between plasma ptau-217 and Flortaucipir-PET in amyloid-positive patients with cognitive impairment ', Alzheimer's and Dementia, vol. 18, no. S1, e067888 . https://doi.org/10.1002/alz.067888
Alzheimer's and Dementia, 18(S1):e067888. Elsevier
Alzheimer's and Dementia, 18(S1):e067888. Elsevier
Background: Plasma measurements of phosphorylated tau (ptau) have emerged as promising biomarkers for Alzheimer’s disease (AD). Studies have shown strong associations between ptau and tau-PET that are mainly driven by the difference between amyloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4396d224fefb3612b1b8e8a21f6bbc1b
https://research.vumc.nl/en/publications/aa3cb9b9-79ac-4b7e-8b2f-5101ad41b921
https://research.vumc.nl/en/publications/aa3cb9b9-79ac-4b7e-8b2f-5101ad41b921
Autor:
Nidhi S. Mundada, Julio C. Rojas, Lawren Vandevrede, Elisabeth H. Thijssen, Leonardo Iaccarino, Obiora C. Okoye, Ranjani Shankar, David N. Soleimani-Meigooni, Argentina L. Lago, Bruce L. Miller, Charlotte E. Teunissen, Hillary Heuer, Howie J. Rosen, Jeffrey L. Dage, William J. Jagust, Gil D. Rabinovici, Adam L. Boxer, Renaud La Joie
Background and ObjectivePlasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer’s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences between amyloid-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b323135ca279aa2d44bbd3ff1950e211
https://doi.org/10.1101/2022.11.29.22282851
https://doi.org/10.1101/2022.11.29.22282851
Autor:
Julie Pham, Renaud La Joie, Amelia Strom, Lauren Edwards, Harli Grant, Joel H. Kramer, Taylor J. Mellinger, Katherine L. Possin, Yann Cobigo, David N Soleimani-Meigooni, Suzanne L. Baker, Bruce L. Miller, Amy Wolf, Leonardo Iaccarino, Gil D. Rabinovici, Kaitlin B. Casaletto, Howard J. Rosen, Minseon Kim
Publikováno v:
Neurobiol Aging
We assessed sex differences in amyloid- and tau-PET retention in 119 amyloid positive patients with mild cognitive impairment or Alzheimer’s disease (AD) dementia. Patients underwent 3T-MRI, (11)C-PIB amyloid-PET and (18)F-Flortaucipir tau-PET. Lin
Autor:
Olof Strandberg, Chul Hyoung Lyoo, Adam L. Boxer, Renaud La Joie, Michael J. Pontecorvo, Erik Stormrud, Michael D. Devous, Young Hoon Ryu, Jonas Jögi, Ruben Smith, Edilio Borroni, Oskar Hansson, David N Soleimani-Meigooni, Jae Yong Choi, Rik Ossenkoppele, Hanna Cho, Bruce L. Miller, Tomas Olsson, Gregory Klein, Antoine Leuzy, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Leonardo Iaccarino, Gil D. Rabinovici, Maria Luisa Gorno-Tempini, Sylvia Villeneuve, Carole H. Sudre
Publikováno v:
Ossenkoppele, R, Leuzy, A, Cho, H, Sudre, C H, Strandberg, O, Smith, R, Palmqvist, S, Mattsson-Carlgren, N, Olsson, T, Jögi, J, Stormrud, E, Ryu, Y H, Choi, J Y, Boxer, A L, Gorno-Tempini, M L, Miller, B L, Soleimani-Meigooni, D, Iaccarino, L, la Joie, R, Borroni, E, Klein, G, Pontecorvo, M J, Devous, M D, Villeneuve, S, Lyoo, C H, Alzheimer’s Disease Neuroimaging Initiative, PREVENT-AD Research Group, Rabinovici, G D & Hansson, O 2021, ' The impact of demographic, clinical, genetic, and imaging variables on tau PET status ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 7, pp. 2245-2258 . https://doi.org/10.1007/s00259-020-05099-w
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 48(7), 2245-2258. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 48(7), 2245-2258. Springer Verlag
Purpose A substantial proportion of amyloid-β (Aβ)+ patients with clinically diagnosed Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) are tau PET–negative, while some clinically diagnosed non-AD neurodegenerative disorder
Autor:
Renaud La Joie, Taylor J. Mellinger, Orit H. Lesman-Segev, Udo Eichenlaub, Julie Pham, Amelia Strom, Lauren Edwards, Ida Sonni, Mustafa Janabi, William J. Jagust, Ruben Smith, Alzheimer’s Disease Neuroimaging Initiative, Karine Provost, Suzanne L. Baker, Oskar Hansson, Bruce L. Miller, Leonardo Iaccarino, David N Soleimani-Meigooni, Niklas Mattsson-Carlgren, Gil D. Rabinovici, Rik Ossenkoppele
Publikováno v:
Provost, K, Iaccarino, L, Soleimani-Meigooni, D N, Baker, S, Edwards, L, Eichenlaub, U, Hansson, O, Jagust, W, Janabi, M, la Joie, R, Lesman-Segev, O, Mellinger, T J, Miller, B L, Ossenkoppele, R, Pham, J, Smith, R, Sonni, I, Strom, A, Mattsson-Carlgren, N, For the Alzheimer’s Disease Neuroimaging Initiative (ADNI) & Rabinovici, G D 2021, ' Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 7, pp. 2259-2271 . https://doi.org/10.1007/s00259-020-05152-8
Eur J Nucl Med Mol Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 48(7), 2259-2271. Springer Verlag
Eur J Nucl Med Mol Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 48(7), 2259-2271. Springer Verlag
PURPOSE: To compare rates of tau biomarker positivity (T-status) per the 2018 Alzheimer’s Disease (AD) Research Framework derived from [(18)F]flortaucipir (FTP) PET visual assessment, FTP quantification, and cerebrospinal fluid (CSF) phosphorylated
Autor:
David C. Perry, Adrienne Visani, Renaud La Joie, Mustafa Janabi, Maria Luisa Gorno-Tempini, Bruce L. Miller, Orit H. Lesman-Segev, William J. Jagust, Julie Pham, Taylor J. Mellinger, Amelia Strom, David N Soleimani-Meigooni, Leonardo Iaccarino, Zachary A. Miller, Lauren Edwards, Gil D. Rabinovici, Howard J. Rosen, Suzanne L. Baker
Publikováno v:
Neurology. 96:e650-e661
ObjectiveTo assess whether Alzheimer disease (AD) clinical presentation and APOE4 relate to the burden and topography of β-amyloid (Aβ) and tau pathologies using in vivo PET imaging.MethodsWe studied 119 Aβ-positive symptomatic patients aged 48–